Back to results
US 12,391,959 B2Granted
Adenoviral vectors comprising partial deletions of E3
AssigneeThe Wistar Institute
InventorsHildegund C. J. Ertl, Xiang Yang Zhou
Life of this patent
Estimating the term…
Abstract
This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.
Claims6
A method of inducing an immune response to an antigenic protein in a subject, comprising administering to the subject an immunogenic composition comprising a replication-incompetent adenovirus vector comprising:
- a) open reading frame (ORF) ORF1 and ORF2 of E3 genomic region;
- b) selective deletion of E3 genomic region consisting of ORF3, ORF4, ORF5, ORF6, and ORF7;
- c) at least one ORF selected from the group consisting of ORF8 and ORF9;
- and
- d) at least one ORF encoding the antigenic protein.
2 more elements
Dependencies are inferred from the claim text.